EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort

David Rieger iD, Hannes Becker iD, Bianca Walter, Lorenz Dörner, Sylvia C Kurz iD, Maximilian Niyazi iD, Raphael Bodensohn iD, Manuela Neumann, Olaf Rieß, Christopher Schroeder, Nadja Ballin, Alexander Ott und 14 weitere

Neuro-Oncology Advances · 12.01.2026 · 8 (1)

DOI: 10.1093/noajnl/vdag031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 16.02.2025. Verfasst von David Rieger und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, German…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Else Kröner Forschungskolleg Tübingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular profiling and subsequent discussions in the Molecular Tumor Board (MTB) within the network of Centers for Personalized Medicine (CPM) have expanded therapeutic options for neuro-oncology patients. Here, we present an update of our Tübingen MTB cohort in adult patients with advanced tumors in the nervous system.

Methods

The Tübingen MTB cohort is documented prospectively in a non-interventional observational study MTB@CPM (NCT03503149) focusing on precision medicine for patients with advanced tumors in routine clinical care. Following patient enrolment, molecular profiling was conducted, and targeted therapy recommendations were assigned after interdisciplinary MTB discussion. This was followed by approval of the MTB therapy by the neuro-oncology tumor board and its subsequent implementation.

Results

This is a follow-up and update of adult neuro-oncology patients in MTB@CPM (2016 through data cutoff June 30, 2024). From a total of 1088 patients, 854 patients were presented in the MTB. Molecular-instructed therapy was recommended for 773/854 (90.5%) patients and prioritized by evidence levels. Therapies were initiated in 152/773 (19.7%) patients, and a PFS ratio was available for 131/152 (86.2%) of treated patients with PFS2/PFS1 ratio > 1.3 in 34.4% (45/131).

Conclusions

This follow-up demonstrates the feasibility of precision medicine for adult neuro-oncology patients within the well-structured and quality-assured MTB/CPM workflow and its implementation as an integral part of the clinical routine, leading to a clinical benefit in about one third of all patients.

Schlagwörter

Stichwörter der Autor:innen

biomarkerneuro-oncology

Autor:innen und Institutionen

  • Department of Neurology & Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, Germany (D.R., H.B., B.W., L.D., S.C.K., M.R., G.T.).
  • Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Tübingen, Germany (D.R., H.B., S.C.K., Max.N., R.B., Man.N., U.E., J.S., M.T., M.R., G.T.).
  • Department of Neurosurgery, Eberhard Karls University, Tübingen, Germany (H.B., M.T., M.R.).
  • Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany (Max.N., R.B.).
  • Center for Personalized Medicine Tübingen, Eberhard Karls University, Tübingen, Germany (Max.N., Man.N, O.R., C.S., N.B., A.O., C.R., S.O., F.F., S.S., S.N., U.E., H.S.M., J.S., M.B., N.M., M.T., G.T.).
  • Institute of Pathology and Neuropathology, Department of Neuropathology, Eberhard Karls University, Tübingen, Germany (Man.N, J.S.).

ORCID-Profile: David Rieger, Hannes Becker, Sylvia C Kurz, Maximilian Niyazi, Raphael Bodensohn, Stephan Ossowski, Falko Fend, Sven Nahnsen, Oliver Kohlbacher, Jens Schittenhelm, Nisar Malek, Marcos Tatagiba, Mirjam Renovanz, Ghazaleh Tabatabai

Förderung

  • Else Kröner Forschungskolleg Tübingen

Zitieren

APA

Rieger, D., Becker, H., Walter, B., Dörner, L., Kurz, S. C., Niyazi, M., Bodensohn, R., Neumann, M., Rieß, O., Schroeder, C., Ballin, N., Ott, A., Roggia, C., Ossowski, S., Fend, F., Singer, S., Nahnsen, S., Kohlbacher, O., Ernemann, U., …, & Tabatabai, G. (2026). Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag031

Vancouver

Rieger D, Becker H, Walter B, Dörner L, Kurz SC, Niyazi M, et al. Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag031

BibTeX
@article{Rieger2026,
  author = {Rieger, David and Becker, Hannes and Walter, Bianca and Dörner, Lorenz and Kurz, Sylvia C and Niyazi, Maximilian and Bodensohn, Raphael and Neumann, Manuela and Rieß, Olaf and Schroeder, Christopher and Ballin, Nadja and Ott, Alexander and Roggia, Cristiana and Ossowski, Stephan and Fend, Falko and Singer, Stephan and Nahnsen, Sven and Kohlbacher, Oliver and Ernemann, Ulrike and Sundberg Malek, Holly and Schittenhelm, Jens and Bitzer, Michael and Malek, Nisar and Tatagiba, Marcos and Renovanz, Mirjam and Tabatabai, Ghazaleh},
  title = {Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/noajnl/vdag031}
}
Kostenlos starten →